8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Vaccine Design and Immune Responses (VADER)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,
...ainst Salmonella Typhi, is in clinical trails in South-East Asia, with vaccines against Salmonella Paratyphi, nontyphoidal Salmonella, meningococcus and Shigella in preclinical development. UoB is an international leader in investigating immune responses to bacteria, particularly Salmonellae, and in relating immunity to microbial antigens. The two institutions have forged strong links over the las ...
Voir le projet
2
Participants partenaires
TERMINÉ
European Research Infrastructures for Poverty Related Diseases (EURIPRED)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
...ucture presents a prime opportunity to address other sexually transmitted diseases such as viral hepatitis efficiently and effectively. The overall goal of the EURIPRED is to coordinate and integrate international resources into a single specialised infrastructure to support European HIV, TB, Malaria and Hepatitis B virus and Hepatitis C virus studies from early drug, vaccine and microbicide disco ...
Voir le projet
18
Participants partenaires
TERMINÉ
Leveraging Pharmaceutical Sciences and Structural Biology Training to develop 21st Century Vaccines (PHA-ST-TRAIN-VAC)
Date du début: 1 juin 2016, Date de fin: 31 mai 2020,
...er in vaccine research, development and production and will work in partnership with the vaccine team within USTRATH and the Strathclyde Institute of Pharmacy and Biomedical Sciences, who have an international track-record of translatable and innovative research in immunology, immunomodulation, structural biology, and formulation design and pharmaceutical engineering of vaccine systems. PHA-ST-TRA ...
Voir le projet
2
Participants partenaires
TERMINÉ
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Voir le projet
43
Participants partenaires
TERMINÉ
TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
...ing TB vaccine and biomarker pipeline as well as accelerate development of most promising TB vaccine candidates through early development stages. The proposed approach and involvement of many internationally leading groups in the TB vaccine and biomarker area in TBVAC2020 fully aligns with the Global TB Vaccine Partnerships (GTBVP).
Voir le projet
49
Participants partenaires
TERMINÉ
Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections: An African-European Research Initiative (IDEA)
Date du début: 1 mars 2010, Date de fin: 31 août 2015,
Worm infections are receiving increased attention due to: the wide geographic overlap in occurrence between worms and HIV, TB and malaria; the large proportion of individuals (minimal estimates around 25%) co-infected with worms and HIV/TB/ malaria; the potential risk of increasing disease burden; the very limited understanding of the impact by worm infections on HIV-, TB- and malaria-specific imm ...
Voir le projet
23
Participants partenaires
TERMINÉ
Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)
Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,
"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet
39
Participants partenaires
TERMINÉ
Access to Pharmaceuticals (ATP)
Date du début: 1 oct. 2009, Date de fin: 31 mars 2013,
Access to Pharmaceuticals Equitable access to pharmaceuticals, particularly for developing countries is an essential human right. Various complex impediments hinder access, which is the subject of ongoing multidisciplinary studies. Intellectual Property and product development are two issues that can be used as tools to address the problem of access, particularly to make patented drugs more afford ...
Voir le projet